STOCK TITAN

Cellectis - CLLS STOCK NEWS

Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.

About Cellectis

Cellectis (NASDAQ: CLLS) is a clinical-stage biopharmaceutical company at the forefront of gene-editing technologies, dedicated to developing innovative cancer immunotherapies and other therapeutic solutions. Leveraging over 18 years of expertise in genome engineering, Cellectis has established itself as a pioneer in the field, utilizing its proprietary TALEN® (Transcription Activator-Like Effector Nucleases) technology and PulseAgile electroporation system to create precise, next-generation therapies. These tools enable the company to harness the immune system's power to target and eliminate cancer cells effectively.

Core Focus: Allogeneic CAR-T and Gene-Edited HSPCs

Cellectis specializes in developing allogeneic Chimeric Antigen Receptor T-cells (UCART) for immuno-oncology applications. Unlike traditional autologous CAR-T therapies, which require harvesting and engineering a patient’s own cells, Cellectis’s allogeneic approach uses gene-edited donor cells. This innovation offers scalability, reduced manufacturing costs, and faster availability, making it a game-changer in cancer treatment. Additionally, the company is advancing gene-edited hematopoietic stem and progenitor cells (HSPCs) for therapeutic indications beyond oncology, showcasing its versatility in genome editing.

Proprietary Technologies

Cellectis’s competitive edge lies in its proprietary technologies:

  • TALEN® Technology: A precise and versatile gene-editing tool that enables targeted modifications to DNA, ensuring high specificity and minimal off-target effects.
  • PulseAgile Electroporation System: A cutting-edge delivery platform that enhances the efficiency of introducing genetic material into cells.

These technologies form the backbone of Cellectis’s product pipeline, enabling the development of innovative therapies that address unmet medical needs.

Market Position and Industry Context

Cellectis operates within the rapidly growing fields of immuno-oncology and precision medicine. The global demand for effective cancer therapies continues to rise, driven by advancements in biotechnology and an increasing understanding of the immune system's role in combating diseases. As a clinical-stage company, Cellectis focuses on research and development, with a pipeline of promising product candidates undergoing rigorous clinical trials. However, this stage also presents challenges, including regulatory approvals, high R&D costs, and competition from other biotech firms specializing in gene editing and CAR-T therapies.

Competitive Landscape

Key competitors in the gene-editing and CAR-T therapy space include CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics. Cellectis differentiates itself through its allogeneic approach, which offers significant advantages in scalability and cost-effectiveness. By addressing the limitations of autologous therapies, such as manufacturing complexity and patient-specific variability, Cellectis positions itself as a leader in next-generation cancer immunotherapies.

Challenges and Opportunities

While Cellectis’s innovative approach holds immense promise, the company faces several challenges. These include navigating a complex regulatory environment, managing high development costs, and competing in a crowded market. However, the potential rewards are substantial, with successful therapies offering transformative benefits for patients and significant market opportunities. The company’s focus on leveraging proprietary technologies and addressing unmet medical needs positions it well for long-term success.

Conclusion

Cellectis is a trailblazer in the biopharmaceutical industry, combining cutting-edge gene-editing technologies with a commitment to innovation in cancer immunotherapy and beyond. By leveraging its proprietary TALEN® technology and allogeneic approach, the company aims to revolutionize the treatment landscape, offering scalable, cost-effective solutions to some of the most pressing medical challenges. As a clinical-stage entity, Cellectis represents a high-risk, high-reward opportunity within the dynamic biotechnology sector.

Rhea-AI Summary

Cellectis S.A. (NASDAQ: CLLS) has announced a global offering of 8,800,000 American Depositary Shares (ADS) at a public price of $2.50 per ADS, initiated on February 2, 2023. The offering is set to close around February 7, 2023, pending usual closing conditions. Major shareholders, including Bpifrance and Baillie Gifford, will receive a significant portion of the offering. The company's ordinary shares were temporarily suspended on Euronext Growth on February 3, with trading expected to resume later that day. As a biotechnology entity, Cellectis focuses on gene-editing technologies to develop innovative therapies for various diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.01%
Tags
none
-
Rhea-AI Summary

Cellectis S.A. has launched an underwritten global offering of 8,800,000 American Depositary Shares (ADS) at $2.50 each, aimed at raising approximately $20.2 million post-expenses. The proceeds are intended for clinical development of UCART therapies and general corporate purposes. The offering, scheduled to close on February 7, 2023, will lead to a dilution of approximately 16.2% of existing shares. The offered ADSs will commence trading on the Nasdaq Global Market. Jefferies and Barclays are the joint book-running managers for the offering, which is backed by a 30-day option for underwriters to purchase additional shares. These steps follow Cellectis' strategy to fund its cell and gene therapy advancements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.01%
Tags
none
-
Rhea-AI Summary

Cellectis, a clinical-stage biotechnology company focused on gene-editing therapies, has launched a global offering of $22 million in American Depositary Shares (ADS). Each ADS represents one ordinary share, with a nominal value of €0.05. The offering includes a public offering in the U.S. and a private placement for qualified investors in other countries. Proceeds will support the clinical development of several product candidates and general corporate purposes. The offering size and price will be determined through an accelerated bookbuilding process. Cellectis has been granted the option for underwriters to purchase an additional 15% of the offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.01%
Tags
none
Rhea-AI Summary

Cellectis (NASDAQ: CLLS) announced an amendment to the financial terms of a $20 million convertible note with Cytovia Therapeutics. The amended note allows for automatic conversion into Cytovia's common stock during specific fundamental transactions and also grants Cellectis conversion options upon financing or company sale. Key changes include an increase in the interest rate to 10% per annum, a requirement for 50% repayment by April 30, 2023, and an extension of the final maturity date to June 30, 2023. Cellectis leverages its gene-editing platform for innovative cell and gene therapies targeting difficult medical conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.46%
Tags
none
-
Rhea-AI Summary

Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) announced the merger of Calyxt (NASDAQ: CLXT) and Cibus Global. The all-stock transaction will merge these agriculture-based gene editing companies, combining their resources for trait development and plant breeding. Cellectis holds a 49.1% equity interest in Calyxt, expected to decrease to approximately 2.5% post-merger. The merger requires approvals from Calyxt’s stockholders and Cibus’ members, along with necessary regulatory approvals, with closing anticipated in Q2 2023. The merger aims to leverage the strengths of both companies in gene editing technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.98%
Tags
-
Rhea-AI Summary

The merger between Calyxt and Cibus aims to create a leading entity in precision gene editing and sustainable agriculture. Under the all-stock deal, Calyxt shareholders will retain approximately 5% of the new company, which will operate under the name Cibus Inc. Key applications include enhancing productivity traits in seeds and developing renewable low-carbon ingredients. The merger supports a strong collaboration pipeline with major seed companies, with three productivity traits expected to launch in early 2023. Both companies anticipate significant regulatory developments that could enhance market opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.98%
Tags
Rhea-AI Summary

Cellectis has announced its intention to conduct an at-the-market offering (ATM) of up to $60 million in American Depositary Shares (ADS) as of January 4, 2023. This program is set to run until July 6, 2025, unless terminated earlier. The funds raised will primarily support the clinical development of its gene therapies, including UCART 123 and others. The potential dilution for existing shareholders is estimated at approximately 23.04%. Jefferies LLC will act as the sales agent, with shares issued without preferential rights for existing shareholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.56%
Tags
none
-
Rhea-AI Summary

Cellectis (Nasdaq: CLLS) has entered into a collaboration with Primera Therapeutics, facilitated by Mayflower Bioventures. The partnership aims to develop gene editing therapies targeting mitochondrial diseases, which currently lack effective treatments. Primera will leverage its innovations from the Mayo Clinic to address mutations in mitochondrial DNA. Cellectis will acquire a 19% stake in Primera and may earn up to $750 million in milestone payments as well as royalties. This collaboration emphasizes Cellectis’ commitment to addressing unmet medical needs through gene editing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
none
-
Rhea-AI Summary

Cellectis has secured a €40 million credit facility from the European Investment Bank to advance its UCART product pipeline. The facility is structured in three tranches: €20 million for Tranche A, €15 million for Tranche B, and €5 million for Tranche C, each with specific conditions for disbursement. This financing aims to support the development of allogeneic CAR T-cell therapies targeting severe unmet medical needs. The facility is designed to be minimally dilutive for shareholders, carrying a decreasing fixed interest rate, capitalized annually.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
none
Rhea-AI Summary

Cellectis announced a significant milestone as the first patient was dosed in the U.S. with its UCART22 product candidate, completing the 28-day Dose Limiting Toxicity (DLT) observation period without complications. This achievement underscores Cellectis' in-house manufacturing capabilities, which enhance efficiency in clinical trials for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The company aims to provide timely treatment, controlling the entire process from research and development to clinical manufacturing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
none

FAQ

What is the current stock price of Cellectis (CLLS)?

The current stock price of Cellectis (CLLS) is $1.29 as of March 3, 2025.

What is the market cap of Cellectis (CLLS)?

The market cap of Cellectis (CLLS) is approximately 136.1M.

What does Cellectis specialize in?

Cellectis specializes in developing gene-edited cancer immunotherapies, particularly allogeneic CAR-T cells, and other therapeutic applications using its proprietary TALEN® technology.

How does Cellectis differentiate from competitors?

Cellectis focuses on allogeneic CAR-T therapies, which offer scalability and cost advantages over autologous approaches. Its proprietary TALEN® technology ensures precise gene editing.

What are Cellectis’s proprietary technologies?

Cellectis utilizes TALEN® for precise gene editing and the PulseAgile electroporation system for efficient genetic material delivery into cells.

What challenges does Cellectis face?

As a clinical-stage company, Cellectis faces challenges such as regulatory hurdles, high R&D costs, and competition from other biotech firms in the gene-editing and immunotherapy space.

What is the significance of allogeneic CAR-T therapies?

Allogeneic CAR-T therapies use gene-edited donor cells, providing scalability, reduced manufacturing costs, and faster availability compared to patient-specific autologous therapies.

What market does Cellectis target?

Cellectis targets the immuno-oncology market with its cancer immunotherapies and explores other therapeutic indications through gene-edited hematopoietic stem and progenitor cells.

Who are Cellectis’s main competitors?

Competitors include CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics, all of which focus on gene-editing technologies and related therapies.

What stage of development is Cellectis in?

Cellectis is a clinical-stage biopharmaceutical company, focusing on research, development, and clinical trials for its product candidates.
Cellectis

Nasdaq:CLLS

CLLS Rankings

CLLS Stock Data

136.13M
69.31M
3.87%
15.3%
0.17%
Biotechnology
Healthcare
Link
France
Paris